Crestor, containing rosuvastatin, is a widely prescribed statin medication for managing cholesterol levels. It lowers LDL (bad cholesterol) and triglycerides while raising HDL (good cholesterol), reducing the risk of cardiovascular complications such as heart attacks and strokes. It is a trusted choice for individuals at risk of heart disease or those with high cholesterol.
Benefits of Crestor:
Dosage:
Warnings and Precautions:
Usage Instructions:
Storage Information:
Common Side Effects:
More information about Crestor:
Public Health Research Service WebmdIt lowers bad cholesterol and triglycerides while raising HDL (good cholesterol) Finasteride for patients at risk of cardiovascular events, such as stroke and heart attack, according to a study in the journalClinical Diabetes.
Its approval by the U. S. Food and Drug Administration (FDA) has granted it a 180-day supply, making it the only statin approved for this use. Public health authorities have also strengthened their warnings about the risk of liver problems or serious muscle problems, including kidney issues.
Crestor is not for everyone, including some people with high cholesterol or those at particularly high risk. Crestor can also cause serious muscle problems, such as muscle pain or weakness, in people with a history of muscle disorders. Regular liver function tests may be necessary to monitor Crestor’s effectiveness and to determine if it’s the right treatment for you.
For more information, talk to your doctor.
You should begin taking Crestor at the same time each day.
Initially, one tablet of Crestor will be taken once daily, along with food. It can be taken with or without food.
Crestor can affect blood levels of:
AstraZeneca is pleased to announce that its cholesterol-lowering drug, Crestor, will be rolled out to patients across the U. S. soon to help them manage their cholesterol levels. The drug is the first in a new class of drugs known as statins to lower high-risk cholesterol, which is the primary cause of high-grade prostate cancer. By lowering the levels of LDL and triglycerides, Crestor will help reduce the risk of developing high-grade prostate cancer.
Crestor is a prescription drug known as rosuvastatin, which is the same active ingredient as Crestor in the drug class.
Crestor is the second-biggest selling prescription drug in the U. S., with sales of $1.16 billion in 2009. AstraZeneca has announced it will be rolled out to patients across the U. this year, bringing in $1.7 billion in sales in 2009.
Patients will also benefit from the drug’s potential for a long-term impact. The drug will be launched in the U. in the fourth quarter of 2009, and is expected to have annual U. sales of $3 billion.
The company’s cholesterol-lowering drug, Crestor, will be rolled out to patients across the U. soon to help them manage their cholesterol levels, and the benefits will be felt within the U. in the coming weeks.
The cholesterol-lowering drug, Crestor, will be available in the U. in two strengths, 20 mg and 40 mg, and generic Crestor, in a 20-tablet bottle. The drug is also available as a 90-day supply.
Patients who have a high risk of developing prostate cancer are given a daily pill of 20 mg or 40 mg of Crestor. If a patient develops prostate cancer, they are also given a daily pill of 10 mg of Crestor.
Patients with a moderate risk of prostate cancer are given a daily pill of 40 mg of Crestor. Patients who have a mild risk of prostate cancer are given a daily pill of 20 mg of Crestor. Patients with a severe risk of prostate cancer are given a daily pill of 40 mg of Crestor.
with sales of $1.16 billion in 2009.
The drug will be available in the U. in the fourth quarter of 2009, and will be available in the U. in the same strengths as Crestor, 20 mg and 40 mg. This is expected to have annual U. sales of $3 billion in 2009.
AstraZeneca expects to launch the drug on November 11, 2009.
As part of the drug’s launch, AstraZeneca will also begin a Phase 3 clinical trial in patients with a risk of prostate cancer. The trial will assess how long the risk of prostate cancer will last and will evaluate the benefits of reducing prostate cancer risk by reducing the amount of prostate-specific antigen (PSA) in the blood. It is expected that the trial will allow patients to make informed decisions about their treatment and will provide patients with a plan that enables them to live longer and live healthier.
The company has completed the phase 3 trial and is ready to share data with AstraZeneca in the second quarter of 2010.
The company also expects to begin a phase 3 trial in patients with a risk of prostate cancer in the second half of 2010, which will be conducted at a follow-up time of 2 to 4 months after the last dose. The company will also conduct a follow-up clinical study in patients with prostate cancer and will have the ability to assess whether they will develop new or worsen symptoms.
The company is also expected to begin Phase 4 trials in patients with a risk of prostate cancer in the second half of 2010.
The company will have a Phase 4 trial in patients with a risk of prostate cancer in the second half of 2010, which will be conducted at a follow-up time of 2 to 4 months after the last dose. The company will also have the ability to assess whether patients will have prostate cancer in the second half of 2010.
The company’s Phase 3 clinical trial is expected to be completed in the second half of 2010.
|AstraZeneca’s cholesterol-lowering drug, Crestor, will be rolled out to patients across the U.
Salt Composition in both
Salt Composition
Rosuvastatin 10mg(same for both)
You Searched
Strip of 15 tablets
We only sell the best substitute from top brands
Our Recommendation
Rosugard 10mg Tablet 10s
Strip of 10 tablets
816+ Customers trust this
WHO GMP Certified
Marketed by
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More
Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s
Submit your email address and email address for the first timeUSAOur philosophy and commitment to our customers is to deliver working order to you within 4 working days. Our standard delivery time is 2-3 days. If you have any alternative needs, we will simply split the money sent to you by your chosen delivery partner to ensure a quality product that helps your online presence flourish. Our post delivery services are provided through U Laos America and U Laos New Zealand.
WorldwideOur customers often include international customers, and are easily identifiable. However, the number of international customers also varies depending on the region and the country. You can find a wide range of international customers, including U Lainey and other major cities, if you prefer.
We deliver all over Vietnam, but only through U Laos America and U Laos New Zealand. This delivery method allows us to deliver all orders over an entire year, without regard to time lost. We do not deliver to markets in Indonesia, Bangladesh, China, or South Korea. This delivery method also does not handle international deliveries. You will not be charged any shipping fees unless you are cleared to do so.
We deliver all over the world. However, remember that each shipment requires a signature on the package.
AstraZeneca has agreed to pay $500 million to settle allegations that it failed to adequately warn patients and doctors of the potential adverse effects of its cholesterol-reducing medication Crestor.
The agreement resolves allegations that AstraZeneca failed to adequately warn the American public and health care organization that Crestor, the active ingredient in Crestor, may cause heart attacks and strokes. The company said its actions would not be covered by the agreement.
The suit, filed Monday, alleged that the company failed to properly warn patients and doctors of the potential adverse effects of Crestor.
The suit alleges that AstraZeneca failed to warn patients and doctors that Crestor could cause heart attacks and strokes in patients taking the drug. The suit claims that AstraZeneca knew or should have known of the dangers of Crestor, the active ingredient in Crestor, and that such dangers were inherent in patients taking the drug.
In a press release, AstraZeneca said: "We are pleased to settle this class-action suit, which was brought against us by a number of major pharmaceutical companies, including AstraZeneca, and the U. S. District Court for the District of New Jersey."
In addition, AstraZeneca said it would pay $50 million in damages to the plaintiffs, which include the plaintiffs’ attorneys and other healthcare professionals.
AstraZeneca (NYSE: AZN):AstraZeneca-Teva Pharmaceuticals Industries Ltd.Teva Pharmaceutical Industries Ltd. (Teva) is the global leader in pharmaceuticals, vaccines, diagnostics, and pharmaceuticals products, and is one of the world’s leading pharmaceutical companies. It was established in 2003, and since that time, has grown from a single company to a world leader in specialty pharmaceuticals and biotechnology. Teva has over 100 years of experience in the pharmaceutical industry and is known for its established and well-established brands like Actonel and Crestor.
AstraZeneca (NYSE: AZ):ZenithZenith, the world’s leading pharmaceutical company, is one of the world’s leading pharmaceutical companies.
AstraZeneca:
The lawsuit claims that Teva failed to adequately warn about the risks associated with Crestor and failed to adequately warn patients and doctors of the potential adverse effects of Crestor.
Zentiva
In October 2018, AstraZeneca announced that it had agreed to pay $500 million to settle allegations that it failed to adequately warn patients and doctors of the potential risks of Crestor. The agreement, known as the “Zentiva Agreement,” resolves allegations that AstraZeneca failed to adequately warn patients and doctors about the risks of Crestor, which is also known as “Crestor.”
AstraZeneca will continue to pay $50 million in damages to the plaintiffs and other healthcare professionals. This settlement will help to ensure that patients and doctors do not have to face serious legal and financial risks associated with Crestor.
The settlement will also allow AstraZeneca to continue to manufacture and sell generic Crestor, which is used in both statin and non-statinologic ways. In April 2019, the company signed a new agreement with Teva Pharmaceutical Industries Ltd. ("Teva"), the world’s second-biggest generic pharmaceutical company. Teva will manufacture and sell Crestor under a different brand name, including Actonel, for a different price.
Stade de France Pharmacy